BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

800 related articles for article (PubMed ID: 30064446)

  • 1. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
    Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
    Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
    Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.
    Feng X; Liu H; Zhang Z; Gu Y; Qiu H; He Z
    J Exp Clin Cancer Res; 2017 Sep; 36(1):123. PubMed ID: 28886730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
    Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
    J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.
    Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L
    Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OTU deubiquitinase 5 inhibits the progression of non-small cell lung cancer via regulating p53 and PDCD5.
    Kang XY; Zhang J; Tang L; Huang L; Tong J; Fu Q
    Chem Biol Drug Des; 2020 Aug; 96(2):790-800. PubMed ID: 32248621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation.
    Ning Y; Hui N; Qing B; Zhuo Y; Sun W; Du Y; Liu S; Liu K; Zhou J
    Cell Death Dis; 2019 May; 10(6):414. PubMed ID: 31138778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.
    Wang X; Bao Y; Dong Z; Chen Q; Guo H; Ziang C; Shao J
    Oncotarget; 2017 Jul; 8(30):49033-49043. PubMed ID: 28446729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.
    Songyang Y; Song T; Shi Z; Li W; Yang S; Li D
    Gene; 2021 Feb; 768():145309. PubMed ID: 33197518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia‑induced internalization of connexin 26 and connexin 43 in pulmonary epithelial cells is involved in the occurrence of non‑small cell lung cancer via the P53/MDM2 signaling pathway.
    Zeng SG; Lin X; Liu JC; Zhou J
    Int J Oncol; 2019 Oct; 55(4):845-859. PubMed ID: 31485592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
    Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
    Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway.
    Chen Y; Li H; Zhang W; Qi W; Lu C; Huang H; Yang Z; Liu B; Zhang L
    Toxicol Appl Pharmacol; 2020 Jan; 387():114848. PubMed ID: 31809756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous nuclear ribonucleoprotein A2/B1 regulates the ERK and p53/HDM2 signaling pathways to promote the survival, proliferation and migration of non‑small cell lung cancer cells.
    Kim MK; Choi MJ; Lee HM; Choi HS; Park YK; Ryu CJ
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34109989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.